[Skip to Navigation]
March 1990

D2 Dopamine Receptors in Neuroleptic-Naive Schizophrenic Patients: A Positron Emission Tomography Study With [11C]Raclopride

Author Affiliations

From The Department of Psychiatry and Psychology, The Karolinska Institute, Stockholm, Sweden (Drs Farde, Wiesel, Nordström, and Sedvall); The Karolinska Pharmacy, Stockholm, Sweden (Drs Stone-Elander and Halldin); and Astra Research Center, Södertälje, Sweden (Dr Hall).

Arch Gen Psychiatry. 1990;47(3):213-219. doi:10.1001/archpsyc.1990.01810150013003

• Several groups have reported increased densities of D2 dopamine receptors in the basal ganglia of schizophrenic brains postmortem. The significance of this finding has been questioned, since an upregulation of receptor number may be a neuronal response to neuroleptic drug treatment. We have used positron emission tomography and [11 C]raclopride to examine central D2 dopamine receptor binding in 20 healthy subjects and 18 newly admitted, young, neuroleptic-naive patients with schizophrenia. An in vivo saturation procedure was applied for quantitative determination of D2 dopamine receptor density (Bmax) and affinity (Kd). When the two groups were compared, no significant difference in Bmax or Kd values was found in the putamen or the caudate nucleus. The hypothesis of generally elevated central D2 dopamine receptor densities in schizophrenia was thus not supported by the present findings. In the patients but not in the healthy controls, significantly higher densities were found in the left than in the right putamen but not in the caudate nucleus.

Add or change institution